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In the early 1980s, in their search for systems that import proteins into mitochondria, Yaffe and 
Schatz identified a mutant in the yeast Saccharomyces cerevisiae, mas1 (for mitochondrial 
assembly 1), that accumulates mitochondrial precursor proteins (Table 1).1 In 1988 they cloned 
and sequenced the wild type yeast MAS1 gene (systematic name: YLR163C), which encodes the 
catalytic subunit of the mitochondrial processing protease, a component of the mitochondrial 
import pathway and essential for cell viability.2 Later, homologs of this gene were found in other 
eukaryotes including humans, in which the gene was called PMPCB (Peptidase, mitochondrial 
processing beta subunit).3 Around the same time, in 1986, a new gene was isolated from DNA of 
a human epidermoid carcinoma cell line, identified as a proto-oncogene, and named MAS.4  
Initially the function of the MAS protein was unknown and it was only in the early 2000s that it 
was identified as the G protein-coupled receptor (GPCR) through which angiotensin (Ang)-(1-7) 
signals. Unfortunately, the MAS gene was later renamed by the HUGO Human Gene 
Nomenclature Committee to MAS1 (Full name: MAS1 proto-oncogene, G protein-coupled 
receptor) and also in mouse, rat and all other tetrapods it got the new name Mas1. Fortunately, 
MAS is still an accepted alias of the MAS1 proto-oncogene protein and we will use this name in 
the following to distinguish it from the yeast Mas1 protein. We would also like to suggest that 
the name MAS should be used in future publications. There is no homolog of MAS in any clade 
outside tetrapods.5 However, several homologous genes were discovered in each tetrapod species 
and the name MAS  was given to this new family of receptors, the Mas-related GPCRs 
(Mrgprs).5,6  
The duplication in nomenclature (Table 1) has unfortunately resulted in some misunderstandings 
and confusion in the Ang field, because there are some papers that attribute Ang-(1-7) effects to 
yeast mitochondrial assembly protein 1, Mas1.7-10 This may be especially important in the 
context of interpretation of results and consideration of tools used to interrogate mammalian 
MAS, because it is likely that in some studies antibodies to the yeast Mas1 protein rather than to 
the GPCR MAS may have been used erroneously. To further add to the complexity, the 
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molecular size of the yeast Mas1 protein (̴ 50 kDa) is not that dissimilar to that of human MAS (̴ 
40 kDa) and antibodies against MAS, which we tested, were nonspecific.11 The confusion was 
additionally increased in 2016, when a putative thermostable lipase from a marine Streptomyces 
species was also named Mas1 (Table 1)12. However, at least until now this protein has not been 
confused with MAS.  
The aim of this brief review is to highlight the importance of discriminating between the 
different ‘Mas1’ proteins and to ensure that the GPCR MAS is indeed the protein of interest 
when examining Ang-(1-7) (patho)physiological actions. Here we provide a historical overview 
of MAS and describe the origin of the name and how its functions have been unravelled. 
 
Discovery of MAS as a Proto-oncogene 
The MAS gene was first identified in 1986 using an assay for human oncogenes based on their 
ability to induce tumorigenicity of NIH 3T3 cells in nude mice.13,14 Briefly, NIH 3T3 cells were 
cotransfected with DNA purified from a human tumor along with a G418 selectable marker. 
After selection and growth in culture, the G418 resistant cells were injected into nude mice. 
Several weeks later, DNA from tumors that formed in the mice was purified. The human DNA 
isolated from one of these tumors contained the MAS gene. The name MAS is an abbreviation of 
the last name (Massey) of the person who donated the human tumor from which the MAS gene 
was derived. This gene was cloned and shown to possess the ability to induce NIH 3T3 cells to 
form foci of transformed cells in culture and to form tumors in nude mice.4 Therefore MAS was 
called a proto-oncogene. However, MAS likely did not contribute to the formation of the human 
tumor since the gene did not appear to be rearranged or mutated in the original human tumor 
DNA; rather, the transforming potential of MAS in NIH 3T3 cells appeared to be activated by 
DNA rearrangement and/or amplification during transfection into NIH 3T3 cells.4,15 Moreover 
recent findings have suggested that MAS-activation by Ang-(1-7) could actually be a therapeutic 
target against tumors and has been suggested as a putative anti-cancer treatment .16 
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MAS as Angiotensin II Receptor? 
Already at the time of its discovery, the DNA sequence of the MAS gene was determined and 
shown to encode a protein with a seven-transmembrane domain structure similar to that of 
GPCR.4 Despite the fact that only one protein is encoded by the gene, we recently demonstrated 
that the mouse Mas gene with 4 promoters and 12 exons generates at least 12 different mRNAs 
by alternative splicing at the 5’ untranslated region and is thereby the most complex gene of all 
GPCRs17. In order to define its ligand, Jackson et al.18 expressed MAS in Xenopus oocytes and in 
a mammalian cell line. Oocytes exhibited a dose-dependent induction of an inward current in 
response to angiotensin (Ang) I, II, and III, and in transfected cells Ang II and III led to 
intracellular Ca2+ release and to the initiation of DNA synthesis. Based on these results MAS was 
suggested to be a functional Ang II receptor. However, whereas several follow-up studies 
supported this assumption19-22, Ambroz et al.23 showed that the Ca2+ release after Ang II 
treatment was only observed in MAS-transfected cells additionally expressing endogenous Ang II 
receptors. Cloning of the real Ang II receptor, AT1, in 1991
24,25 and the discovery of a direct 
interaction between MAS and AT1 in 2005,
26,27 partly explained the original observations of 
Jackson et al.18 in Xenopus oocytes and revealed that MAS is not an Ang II receptor per se, but 
modulates AT1 signaling. 
 
Mas as Imprinted Gene? 
In 1994, Mas was reported to be maternally imprinted in mice28 and in human breast tissue,29 i.e., 
one of the two parental Mas alleles was epigenetically silenced. The Mas gene is located in close 
proximity to the imprinted Igf2r gene in the human and mouse genomes.30,31 Imprinting of this 
chromosomal area is regulated by an intronic control element starting the transcription of the 
long noncoding RNA, Airn (Antisense Igf2r RNA Noncoding). The transcribed antisense RNA 
overlaps (and silences) the Igf2r promoter and partially the Mas gene.32,33 Using Mas-deficient 
mice34 we could show that Mas is biallelically expressed.34 Since Villar and Pedersen28 and 
5 
 
Miller et al.,29 used RT-PCR assays which lack strand selectivity to discover imprinting of Mas it 
is very likely that they detected Airn as maternally imprinted RNA and not the Mas transcript. 
Thus, Airn but not Mas is monoallelically expressed in mouse and man. 
 
MAS as Angiotensin-(1-7) Receptor  
The first evidence for a receptor for Ang-(1-7) distinct from the Ang II receptors came from the 
observation that Ang-(1-7) was equipotent to Ang II for vasopressin release from hypothalamus-
neurohypophyseal explants,36 but in contrast to Ang II had no effect on drinking behavior.37 
Moreover, Ang-(1-7) was reported to exert vasodilatory effects by releasing NO resulting in a 
blood pressure decrease.38 This and other actions of Ang-(1-7), which all opposed the effects of 
Ang II, further supported that Ang-(1-7) mediates its effects through a novel non-AT1/AT2 
receptor subtype. The final proof for the existence of a specific receptor for the peptide was the 
discovery of a selective antagonist for Ang-(1-7) in 1994.39,40   
Yet, it was only in 2003 that more definitive evidence for a specific binding site for Ang-(1-7) 
was demonstrated with the finding that MAS is a receptor for the heptapeptide.41 In that study, 
specific binding of 125I-Ang-(1-7) to Mas-transfected cells was reported. Moreover, the specific 
binding of 125I-Ang-(1-7) but not of 125I-Ang II or 125I-Ang IV to kidney sections, was abolished 
by genetic deletion of Mas. In addition, Mas-deficient mice completely lack the antidiuretic 
action of Ang-(1-7) after an acute water load and Mas-deficient aortas lost their Ang-(1-7)-
induced relaxation response. These findings provided the first clear molecular basis for the 
physiological actions of this biologically active peptide. At this point an orphan receptor met an 
orphan peptide filling an important gap in our understanding of the renin-angiotensin system. 
Further support for these findings was obtained in different laboratories. In 2005, Tallant et al.42 
showed that transfection of cultured myocytes with an antisense oligonucleotide to Mas blocked 
the Ang-(1-7)-mediated inhibition of serum-stimulated MAPK activation, whereas a sense 
oligonucleotide was ineffective. Ang-(1-7) was found to stimulate NO release and eNOS 
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activation in endothelial cells and these effects were blocked by the specific MAS-antagonist, A-
77943,44. In addition, Mas-deficiency abolishes all the known cardiovascular effects of Ang-(1-
7).45 Indeed, in most instances genetic deletion of Mas causes alterations opposed to those 
produced by treatment with Ang-(1-7).  
Nevertheless, there are recent reports that Ang-(1-7) has no effect on MAS-transfected cells but 
exerts biased agonism or even antagonism at the AT1 receptor.
46-48 Moreover, using other MAS 
agonists (NPFF and AR234960) and inverse agonists (AR244555) biased signaling of MAS 
itself was described.49 Heteromeric interactions of MAS with AT1, AT2, bradykinin B2 and 
endothelin B receptors further complicate this issue.26,27,50-52  Therefore future studies need to 
clarify the relationship between MAS and Ang-(1-7) which may depend on the specific cell 
types and their expression of other GPCRs.53  
Conclusions 
In conclusion, this brief review highlights some important points related to some misconceptions 
and confusions regarding the nomenclature of MAS and its functions (Table), especially in the 
context of cardiovascular pathophysiology. We suggest that the original name of “Mas” be used 
for the GPCR.  
Important take home messages  
1. The MAS1 gene in yeast codes for Mas1p (mitochondrial assembly protein 1) a protease 
essential for protein import into mitochondria and homologous to the human PMPCB 
gene. 
2. MAS1 or MAS in tetrapods is a G protein-coupled receptor for Ang-(1-7), but not for 
Ang II. 
3. Yeast Mas1 protein has a molecular size of 50-52 kDa, while mammalian MAS has a 
molecular size of 37-40 kDa.  
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4. When probing for MAS1 or MAS in the context of Ang-(1-7) biology, ensure the correct 
primers and antibodies are used to assess expression of mRNA and protein respectively. 
It should be noted though that currently the authors are unaware of commercially 
available antibodies that specifically detect MAS at physiological expression levels. 
However, we demonstrated that the following primer pair is suitable to quantify human 
MAS mRNA by qPCR and may also be used in mice: 5’-
GCTACAACACGGGCCTCTATCTG-3’; 5’-TACTCCATGGTGGTCACCAAGC-3’, 
fragment length 160 bp. 
5. The mouse Mas gene is not imprinted. 
6. The MAS gene is a proto-oncogene, but has not yet been shown to cause a human tumor. 
7. Ang-(1-7)/MAS mediates effects that oppose actions of Ang II/AT1. 
8. MAS interacts with other G protein-coupled receptors. 
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